JP2013529181A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013529181A5 JP2013529181A5 JP2013501487A JP2013501487A JP2013529181A5 JP 2013529181 A5 JP2013529181 A5 JP 2013529181A5 JP 2013501487 A JP2013501487 A JP 2013501487A JP 2013501487 A JP2013501487 A JP 2013501487A JP 2013529181 A5 JP2013529181 A5 JP 2013529181A5
- Authority
- JP
- Japan
- Prior art keywords
- pkd1
- antibody
- human mammal
- mammal
- endogenous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101001026870 Homo sapiens Serine/threonine-protein kinase D1 Proteins 0.000 claims 14
- 102100037310 Serine/threonine-protein kinase D1 Human genes 0.000 claims 14
- 101100029888 Homo sapiens PKD1 gene Proteins 0.000 claims 6
- 101150056230 PKD1 gene Proteins 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 230000002452 interceptive effect Effects 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000007812 deficiency Effects 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 210000002569 neuron Anatomy 0.000 claims 3
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 230000007547 defect Effects 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 239000004055 small Interfering RNA Substances 0.000 claims 2
- 230000009261 transgenic effect Effects 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000004498 neuroglial cell Anatomy 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 150000003384 small molecules Chemical group 0.000 claims 1
- 230000006886 spatial memory Effects 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31759810P | 2010-03-25 | 2010-03-25 | |
| US61/317,598 | 2010-03-25 | ||
| PCT/US2011/029806 WO2011119842A1 (en) | 2010-03-25 | 2011-03-24 | Compositions and methods for treating neurological disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013529181A JP2013529181A (ja) | 2013-07-18 |
| JP2013529181A5 true JP2013529181A5 (enExample) | 2014-05-08 |
Family
ID=44673620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013501487A Pending JP2013529181A (ja) | 2010-03-25 | 2011-03-24 | 神経障害を治療するための組成物および方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US9359445B2 (enExample) |
| EP (1) | EP2550361B1 (enExample) |
| JP (1) | JP2013529181A (enExample) |
| WO (1) | WO2011119842A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160178610A1 (en) * | 2013-08-07 | 2016-06-23 | Friedrich Miescher Institute For Biomedical Research | New screening method for the treatment Friedreich's ataxia |
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| EP3201339A4 (en) | 2014-10-03 | 2018-09-19 | Cold Spring Harbor Laboratory | Targeted augmentation of nuclear gene output |
| KR20220105174A (ko) | 2015-10-09 | 2022-07-26 | 유니버시티 오브 사우스앰톤 | 유전자 발현의 조절 및 탈조절된 단백질 발현의 스크리닝 |
| US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| WO2017106377A1 (en) | 2015-12-14 | 2017-06-22 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome |
| EP3580700A4 (en) * | 2017-02-09 | 2020-11-18 | Cognoa, Inc. | PLATFORM AND SYSTEM FOR DIGITAL PERSONALIZED MEDICINE |
| EP3611696A4 (en) | 2017-02-16 | 2021-02-17 | Kyoto University | CELL EVALUATION DEVICE, CELL EVALUATION METHOD AND CELL EVALUATION PROGRAM |
| CA3070446A1 (en) | 2017-07-25 | 2019-01-31 | Immutics, Inc. | Treating cancer by blocking the interaction of tim-3 and its ligand |
| KR20240035631A (ko) | 2017-08-25 | 2024-03-15 | 스톡 테라퓨틱스, 인크. | 병태 및 질환 치료용 안티센스 올리고머 |
| WO2019213525A1 (en) | 2018-05-04 | 2019-11-07 | Stoke Therapeutics, Inc. | Methods and compositions for treatment of cholesteryl ester storage disease |
| CN120058944A (zh) | 2019-01-30 | 2025-05-30 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| KR20230022409A (ko) | 2020-05-11 | 2023-02-15 | 스톡 테라퓨틱스, 인크. | 병태 및 질환의 치료를 위한 opa1 안티센스 올리고머 |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3257675B2 (ja) | 1990-10-12 | 2002-02-18 | マックス−プランク−ゲゼルシャフト ツール フェルデルング デル ビッセンシャフテン エー．ファウ． | 修飾リボザイム |
| DE4216134A1 (de) | 1991-06-20 | 1992-12-24 | Europ Lab Molekularbiolog | Synthetische katalytische oligonukleotidstrukturen |
| US5652094A (en) | 1992-01-31 | 1997-07-29 | University Of Montreal | Nucleozymes |
| CA2154363A1 (en) | 1993-01-22 | 1994-08-04 | Bruce A. Sullenger | Localization of therapeutic agents |
| US5627053A (en) | 1994-03-29 | 1997-05-06 | Ribozyme Pharmaceuticals, Inc. | 2'deoxy-2'-alkylnucleotide containing nucleic acid |
| US5716824A (en) | 1995-04-20 | 1998-02-10 | Ribozyme Pharmaceuticals, Inc. | 2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes) |
| US7964598B2 (en) | 1995-10-17 | 2011-06-21 | The J. David Gladstone Institutes | ApoE4 domain interaction inhibitors and methods of use thereof |
| DE69637256T2 (de) | 1996-01-16 | 2008-06-19 | Sirna Therapeutics, Inc., Boulder | Synthese von Methoxynukleoside und enzymatische Nukleisäure Moleküle |
| US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| DE19650758C1 (de) * | 1996-12-06 | 1998-01-02 | Deutsches Krebsforsch | PKD1-Fragmente mit Bindungsregionen für PKD1-spezifische Antikörper |
| US6124272A (en) * | 1999-04-09 | 2000-09-26 | Isis Pharmaceutical Inc. | Antisense modulation of PDK-1 expression |
| US20050233329A1 (en) | 2002-02-20 | 2005-10-20 | Sirna Therapeutics, Inc. | Inhibition of gene expression using duplex forming oligonucleotides |
| US7491805B2 (en) | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US20050282188A1 (en) | 2001-05-18 | 2005-12-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
| CA2526831C (en) | 2001-05-18 | 2012-07-31 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina) |
| GB0117326D0 (en) | 2001-07-16 | 2001-09-05 | Univ Aberdeen | Napthoquinone-type inhibitors of protein aggregation |
| AR036604A1 (es) | 2001-09-21 | 2004-09-22 | Mitsubishi Pharma Corp | Derivados de 4-pirimidona 3-sustituida |
| US20040121407A1 (en) * | 2002-09-06 | 2004-06-24 | Elixir Pharmaceuticals, Inc. | Regulation of the growth hormone/IGF-1 axis |
| JP2007511618A (ja) | 2003-11-19 | 2007-05-10 | シグナル ファーマシューティカルズ，エルエルシー | インダゾール化合物およびタンパク質キナーゼ阻害剤としてのその使用方法 |
| PT1893612E (pt) | 2005-06-22 | 2011-11-21 | Plexxikon Inc | Derivados de pirrolo [2,3-b]piridina como inibidores de proteína quinase |
| GB0602178D0 (en) * | 2006-02-03 | 2006-03-15 | Merck Sharp & Dohme | Therapeutic treatment |
| AU2007245496A1 (en) | 2006-04-26 | 2007-11-08 | Cancer Research Technology Limited | Amino-ethyl-amino-aryl (AEAA) compounds and their use |
| US20090175852A1 (en) | 2006-06-06 | 2009-07-09 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
| US8240498B2 (en) | 2006-10-31 | 2012-08-14 | Crown Packaging Technology, Inc. | Resealable closure |
| US8618063B2 (en) * | 2008-04-09 | 2013-12-31 | The Board Of Trustees Of The University Of Illinois | Method for treating a synucleinopathy |
| WO2009147246A1 (en) * | 2008-06-06 | 2009-12-10 | Medizinische Universität Graz | Compounds reducing or inhibiting the expression of pkd1 for diagnosis and therapy of brain tumors |
| ES2385276B1 (es) | 2010-02-25 | 2013-07-05 | Universidad Del País Vasco | Compuestos para el tratamiento de alzheimer. |
-
2011
- 2011-03-24 WO PCT/US2011/029806 patent/WO2011119842A1/en not_active Ceased
- 2011-03-24 JP JP2013501487A patent/JP2013529181A/ja active Pending
- 2011-03-24 EP EP11760223.5A patent/EP2550361B1/en not_active Not-in-force
-
2012
- 2012-09-24 US US13/625,597 patent/US9359445B2/en not_active Expired - Fee Related
-
2016
- 2016-05-05 US US15/147,814 patent/US20160354372A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013529181A5 (enExample) | ||
| Carty et al. | Characterization of HTT inclusion size, location, and timing in the zQ175 mouse model of Huntington´ s disease: an in vivo high-content imaging study | |
| Hansen et al. | A novel α-synuclein-GFP mouse model displays progressive motor impairment, olfactory dysfunction and accumulation of α-synuclein-GFP | |
| Park et al. | MTERF3 is a negative regulator of mammalian mtDNA transcription | |
| Zaharieva et al. | Concentration and localization of coexpressed ELAV/Hu proteins control specificity of mRNA processing | |
| Tanaka et al. | BEX1/ARF1A1C is required for BFA-sensitive recycling of PIN auxin transporters and auxin-mediated development in Arabidopsis | |
| Hallengren et al. | Neuronal ubiquitin homeostasis | |
| Nagara et al. | Impaired Cytoplasmic–Nuclear Transport of Hypoxia‐Inducible Factor‐1α in Amyotrophic Lateral Sclerosis | |
| HRP20231707T1 (hr) | Životinje koje nisu ljudi, koje sadrže humanizirani gen iz diferencijacijske skupine 47 | |
| JP2011501652A5 (enExample) | ||
| Tulgren et al. | The Nesprin family member ANC-1 regulates synapse formation and axon termination by functioning in a pathway with RPM-1 and β-Catenin | |
| Razafsky et al. | LINC complexes mediate the positioning of cone photoreceptor nuclei in mouse retina | |
| Navarro et al. | The nucleus is a conserved mechanosensation and mechanoresponse organelle | |
| Pelletier et al. | An early onset progressive motor neuron disorder in Scyl1-deficient mice is associated with mislocalization of TDP-43 | |
| HRP20202034T1 (hr) | Neljudske životinje s genom za humanizirani diferencijacijski biljeg cd274 | |
| JP2016527891A5 (enExample) | ||
| Becker et al. | Glutaminyl cyclase-mediated toxicity of pyroglutamate-beta amyloid induces striatal neurodegeneration | |
| JP2009525046A5 (enExample) | ||
| Wang et al. | Sun1 deficiency leads to cerebellar ataxia in mice | |
| Yamamoto et al. | The nebulin SH3 domain is dispensable for normal skeletal muscle structure but is required for effective active load bearing in mouse | |
| Kong et al. | Dlic1 deficiency impairs ciliogenesis of photoreceptors by destabilizing dynein | |
| Abrakhi et al. | Nanoscale analysis reveals the maturation of neurodegeneration-associated protein aggregates: grown in mRNA granules then released by stress granule proteins | |
| Tomioka et al. | Ependymal cells of the mouse brain express urate transporter 1 (URAT1) | |
| WO2013052814A3 (en) | E1 enzyme mutants and uses thereof | |
| JP6606428B2 (ja) | 脊髄小脳変性症を予防又は治療するための薬剤 |